You are viewing the site in preview mode

Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

Journal for ImmunoTherapy of Cancer20197:94

https://doi.org/10.1186/s40425-019-0571-7

  • Received: 20 March 2019
  • Accepted: 20 March 2019
  • Published:

The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:75

Correction to: J Immunother Cancer 2019 7:75

https://doi.org/10.1186/s40425-019-0525-0

Following publication of the original article [1], the author reported two errors in the authors affiliations:

1. Dr. Song Cheol Kim should be affiliated to Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery,University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea;

2. Dr. Eun Sung Jun should be affiliated to Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea and to Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery,University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea;

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
(2)
Cancer Biology Research Center, Hangzhou, China
(3)
Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, TX, USA
(4)
Zhejiang Provincial Key Laboratory for Precision Diagnosis & Treatment of Hepatic & Pancreatic Oncology, Hangzhou, Zhejiang Province, China
(5)
Division of Hepatobiliary & Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
(6)
Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea
(7)
Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
(8)
Department of Laboratory Medicine, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, China

Reference

  1. Yao et al. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy. Journal for ImmunoTherapy of Cancer. 2019;7:75. https://doi.org/10.1186/s40425-019-0525-0.View ArticleGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement